Kane Biotech was preparing the annual financial statements and, as part of the year-end procedures, assessed the assets and prepared the following alphabetized schedule based on adjusted values at December 31, 2023: (Do not round intermediate calculations. Round final answers to nearest whole dollar.)

AssetDate of PurchaseDeprec. Method*CostResidual ValueUseful LifeAccum. Deprec.Recoverable Amount EquipmentMay 1/18Units$49,000 $2,390 7,900 units$28,910 $5,390 FurnitureJun. 28/18DDB 21,000 2,900 8 yrs 17,339 3,850 LandApr. 5/18N/A 94,000 N/A N/A N/A 110,800 Office buildingApr. 5/18SL 95,000 25,100 15 yrs 31,100 61,500 WarehouseApr. 5/18SL 68,500 19,000 20 yrs 21,938 54,100

*DDB = Double-declining-balance; SL = Straight-line; Units = Units-of-production; N/A = Not applicable Required: 1. Record any impairment losses at December 31, 2023. Assume Kane Biotech has recorded no impairment losses in previous years.